Since 1977 patients under the care of the Birmingham bone tumour treatment service with pulmonary metastases from osteogenic sarcoma have been referred immediately to a thoracic surgery unit for assessment of suitability for resection. This paper compares the survival of patients who underwent resection of their metastases with that of those who did not undergo resection and looks at the response in relation to prognostic indicators.
developed pulmonary metastases out of the '11 patients with osteosarcoma treated by the Birmingham bone tumour treatment service during 1977- 83. All patients who developed metastases confined to the lungs were considered for resection, thoracotomy being advised for all patients (provided that they were fit enough) who had metastases thought to be resectable even if they were multiple. Results Of the 18 patients who did not have a thoracotomy, 15 died of disseminated disease after a mean interval of eight months; one patient died of cardiomyopathy and two are alive after 26 and eight months. Of the 25 patients who underwent thoracotomy in an attempt to resect metastases, three were found to have inoperable disease and died after a mean interval of 5*4 months from thoracotomy. Overall, after thoracotomy (repeated if necessary) there was a 20% survival at five years from the first thoracotomy. When survival was assessed with respect to the disease free interval and the number and bilaterality of the metastases no significant relationships were found. There was, however, a significant relation between survival and the position of metastases, patients with metastases confined to one lobe of the lung having a mean survival of 29 5 months, compared with 13-7 months in patients with disease in more than one lobe. Conclusion Thus patients who had a thoracotomy survived longer from the time of diagnosis of pulmonary metastasis than those not undergoing thoracotomy; metastases confined to one lobe predicted a better prognosis. The average duration of symptoms was 13-1 weeks. The site of the primary tumour was the femur in 56 patients; tibia in 31; humerus in 16; fibula in three; ilium in two; and ribs, ischium, and clavicle in one patient each.
The surgical treatment of the primary tumour was amputation for 16 patients, excision for six, and endoprosthetic replacement for 89.
All patients received chemotherapy at the time of surgical treatment. Fifty seven patients received 11 weeks' high dosage methotrexate of 3-7.5 g/m2 body surface area with leucovorin rescue. Twenty nine had vincristine, doxorubicin (Adriamycin) and low dose methotrexate. The remaining patients had various other chemotherapy regimens.
The patients were reviewed regularly after treatment, initially at three monthly intervals until two years after completion of treatment and thereafter six monthly. At each attendance posteroanterior and lateral radiographs of the chest were performed routinely.
All patients who developed metastases confined to the lungs were referred to a thoracic surgeon for assessment with a view to possible resection. As it was uncertain whether resection of bilateral metastases is worth while, thoracotomy was advised for all patients in whom the metastases, even if multiple, were thought to be capable of total resection, provided that the patient was fit enough to undergo the procedure.
After thoracotomy and resection of metastases 13 patients were given adjuvant chemotherapy and 10 patients did not receive chemotherapy.
The results were assessed by standard statistical methods. Aleans were compared by Twenty five patients underwent thoracotomy. At surgery the disease was found to be too extensive for any attempt at resection in three patients. In the remaining 22 patients the resection resulted in complete removal of clinically apparent disease. Eleven resections were performed for a single metastasis and 11 for multiple metastases. In 14 patients the metastases were confined to a single lobe of the lung whereas eight had metastases in more than one lobe. In the four patients with bilateral disease resections were performed through a median sternotomy. Two patients had two thoracotomies and two had three thoracotomies for recurrence of metastases. The mean time between the first and second thoracotomy was 15 7 (range 7-24) months and between the second and third was 17-5 (range 8-33) months. Of the four patients who underwent multiple thoracotomies, one is alive and free of disease 89 months after the first thoracotomy (39 months after the third thoracotomy). The other three patients have died an average of 51 months from the onset of their pulmonary metastases. 40 50 60
Disease free interval (months The number of pulmonary metastases resected showed no significant relation to the time taken for the initial-pulmonary metastases to appear, or to survival from the appearance of the metastases. There was also no significant relation between survival and whether the pulmonary metastases were unilateral or bilateral, or between the disease free interval and survival (fig 2) .
Discussion
In recent years a change in the distribution of metastatic disease arising from osteosarcoma appears to have taken place, with a decrease in the proportion of pulmonary metastases'2 but an increase in the number of bony metastases. 3 This may be a result of a natural alteration in the disease process with time'4 but is more likely to be due to improvements in adjuvant chemotherapy,'5 resulting in longer survival or to more sensitive diagnostic aids such as computed tomography.
Patients who died of their disease after thoracotomy must have had other metastases present at the time of the resection that were teosarcomatreateduptothe not detected. Identifying the extent of the agnosis of osteosarcoma; b disease before resection is therefore essential. patients who underwent Gundry'6 concluded that the presence of tastases of the 18 patients who tumour microfoci in the pulmonary resection specimens was associated with an increased recurrence rate. Detailed histological assessment of the resected specimen may improve after thoracotomy; the 18 patients with resectable disease died a median of 24 (1 8-77) months after thoracotomy. Sixteen died of disseminated malignancy, one of doxorubicin cardiotoxicity at nine months, and one of an unrelated cause 27 months after thoracotomy. There were no operative deaths. The median survival of eight months in patients not undergoing resection of pulmonary metastases compared with 24 months in those who underwent resection.
The five year survival rate from the time of first resection was 20%. This is shown on a cumulative survival curve (fig 3) . FACTORS We conclude from this study that thoracotomy may increase survival after the development of pulmonary metastases, though it is unlikely to cure the patient. Our results may be improved by more careful review of the patients, with the use of computed tomography, to attempt to detect metastases at an earlier stage and to identify those with disease confined to one lobe of the lung.
